Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agree… Read more
Innovation Pharmaceuticals Inc (IPIX) - Total Assets
Latest total assets as of September 2023: $6.67 Million USD
Based on the latest financial reports, Innovation Pharmaceuticals Inc (IPIX) holds total assets worth $6.67 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Innovation Pharmaceuticals Inc - Total Assets Trend (2006–2023)
This chart illustrates how Innovation Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Innovation Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (June 2023)
Innovation Pharmaceuticals Inc's total assets of $6.67 Million consist of 21.7% current assets and 78.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.00 Million | 26.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2023)
This chart illustrates how Innovation Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Innovation Pharmaceuticals Inc's current assets represent 21.7% of total assets in 2023, a decrease from 41.6% in 2006.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2023, down from 41.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, a decrease from 58.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 26.6% of total assets.
Innovation Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Innovation Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Innovation Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Innovation Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Innovation Pharmaceuticals Inc is currently not profitable relative to its asset base.
Innovation Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 0.60 | 0.11 |
| Quick Ratio | 0.19 | 0.60 | 0.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.11 Million | $ -2.04 Million | $ -7.11 Million |
Innovation Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Innovation Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -27.6% |
| Total Assets | $7.52 Million |
| Market Capitalization | $102.82K USD |
Valuation Analysis
Below Book Valuation: The market values Innovation Pharmaceuticals Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Innovation Pharmaceuticals Inc's assets decreased by 27.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Innovation Pharmaceuticals Inc (2006–2023)
The table below shows the annual total assets of Innovation Pharmaceuticals Inc from 2006 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-06-30 | $7.52 Million | -27.57% |
| 2022-06-30 | $10.38 Million | -27.41% |
| 2021-06-30 | $14.30 Million | +54.62% |
| 2020-06-30 | $9.25 Million | +128.57% |
| 2019-06-30 | $4.05 Million | -38.14% |
| 2018-06-30 | $6.54 Million | -28.22% |
| 2017-06-30 | $9.11 Million | -20.38% |
| 2016-06-30 | $11.45 Million | -20.07% |
| 2015-06-30 | $14.32 Million | +31.95% |
| 2014-06-30 | $10.85 Million | +265.32% |
| 2013-06-30 | $2.97 Million | +10498.38% |
| 2012-06-30 | $28.03K | -91.05% |
| 2011-06-30 | $313.10K | +207.50% |
| 2010-06-30 | $101.82K | -34.41% |
| 2009-06-30 | $155.23K | -65.49% |
| 2008-06-30 | $449.78K | +1841.04% |
| 2007-06-30 | $23.17K | +11.63% |
| 2006-06-30 | $20.76K | -- |